相似文献
1
Malaria vaccine research & innovation: the intersection of IA2030 and zero malaria.
NPJ Vaccines. 2020 Nov 20;5(1):109. doi: 10.1038/s41541-020-00259-3.
2
Accelerating access for all through research and innovation in immunization: Recommendations from Strategic Priority 7 of the Immunization Agenda 2030.
Vaccine. 2024 Apr 8;42 Suppl 1:S82-S90. doi: 10.1016/j.vaccine.2022.11.041. Epub 2022 Dec 16.
3
Achieving the IA2030 Coverage and Equity Goals through a Renewed Focus on Urban Immunization.
Vaccines (Basel). 2023 Apr 6;11(4):809. doi: 10.3390/vaccines11040809.
4
Global vaccine action plan lessons learned I: Recommendations for the next decade.
Vaccine. 2020 Jul 14;38(33):5364-5371. doi: 10.1016/j.vaccine.2020.05.003. Epub 2020 May 5.
5
Producing a successful malaria vaccine: innovation in the lab and beyond.
Health Aff (Millwood). 2011 Jun;30(6):1065-72. doi: 10.1377/hlthaff.2011.0356.
6
Building momentum for malaria vaccine research and development: key considerations.
Malar J. 2020 Nov 23;19(1):421. doi: 10.1186/s12936-020-03491-3.
7
A Systematic Framework for Prioritizing Burden of Disease Data Required for Vaccine Development and Implementation: The Case for Group A Streptococcal Diseases.
Clin Infect Dis. 2022 Sep 30;75(7):1245-1254. doi: 10.1093/cid/ciac291.
8
Plasmodium vivax transmission-blocking vaccines: Progress, challenges and innovation.
Parasitol Int. 2022 Apr;87:102525. doi: 10.1016/j.parint.2021.102525. Epub 2021 Dec 9.
9
Paths to a malaria vaccine illuminated by parasite genomics.
Trends Genet. 2015 Feb;31(2):97-107. doi: 10.1016/j.tig.2014.12.005. Epub 2015 Jan 22.
10
Effect of intermittent preventive treatment for malaria with dihydroartemisinin-piperaquine on immune responses to vaccines among rural Ugandan adolescents: randomised controlled trial protocol B for the 'ulation differences in cine responses' (POPVAC) programme.
BMJ Open. 2021 Feb 16;11(2):e040427. doi: 10.1136/bmjopen-2020-040427.
引用本文的文献
1
Innovative Multistage ML-QSAR Models for Malaria: From Data to Discovery.
ACS Med Chem Lett. 2024 Jul 18;15(8):1386-1395. doi: 10.1021/acsmedchemlett.4c00323. eCollection 2024 Aug 8.
2
Subcutaneous Immunization with Unaltered Axenic Malaria Parasite Liver Stages Induces Sterile Protection against Infectious Sporozoite Challenge.
Vaccines (Basel). 2022 Nov 8;10(11):1884. doi: 10.3390/vaccines10111884.
3
Genetic diversity and immunogenicity of the merozoite surface protein 1 C-terminal 19-kDa fragment of Plasmodium ovale imported from Africa into China.
Parasit Vectors. 2021 Nov 24;14(1):583. doi: 10.1186/s13071-021-05086-6.
4
Towards Eradication of Malaria: Is the WHO's RTS,S/AS01 Vaccination Effective Enough?
Risk Manag Healthc Policy. 2021 Mar 12;14:1033-1039. doi: 10.2147/RMHP.S219294. eCollection 2021.
本文引用的文献
1
Immunization agenda 2030: A global strategy to leave no one behind.
Vaccine. 2024 Apr 8;42 Suppl 1:S5-S14. doi: 10.1016/j.vaccine.2022.11.042.
2
Malaria vaccines since 2000: progress, priorities, products.
NPJ Vaccines. 2020 Jun 9;5(1):48. doi: 10.1038/s41541-020-0196-3. eCollection 2020.
3
Evolution of protective human antibodies against Plasmodium falciparum circumsporozoite protein repeat motifs.
Nat Med. 2020 Jul;26(7):1135-1145. doi: 10.1038/s41591-020-0881-9. Epub 2020 May 25.
4
Antibody response of a particle-inducing, liposome vaccine adjuvant admixed with a Pfs230 fragment.
NPJ Vaccines. 2020 Mar 18;5(1):23. doi: 10.1038/s41541-020-0173-x. eCollection 2020.
5
Amplification of Duffy binding protein-encoding gene allows Plasmodium vivax to evade host anti-DBP humoral immunity.
Nat Commun. 2020 Feb 19;11(1):953. doi: 10.1038/s41467-020-14574-9.
6
Immunization with full-length merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial.
NPJ Vaccines. 2020 Jan 31;5(1):10. doi: 10.1038/s41541-020-0160-2. eCollection 2020.
7
AgBR1 antibodies delay lethal -borne West Nile virus infection in mice.
NPJ Vaccines. 2019 Jul 8;4:23. doi: 10.1038/s41541-019-0120-x. eCollection 2019.
8
Structural basis for inhibition of Plasmodium vivax invasion by a broadly neutralizing vaccine-induced human antibody.
Nat Microbiol. 2019 Sep;4(9):1497-1507. doi: 10.1038/s41564-019-0462-1. Epub 2019 May 27.
9
Structural basis for neutralization of Plasmodium vivax by naturally acquired human antibodies that target DBP.
Nat Microbiol. 2019 Sep;4(9):1486-1496. doi: 10.1038/s41564-019-0461-2. Epub 2019 May 27.
10
Pregnant women & vaccines against emerging epidemic threats: Ethics guidance for preparedness, research, and response.
Vaccine. 2021 Jan 3;39(1):85-120. doi: 10.1016/j.vaccine.2019.01.011. Epub 2019 May 3.
Zotero 插件